The Commonwealth Serum Laboratories was established in Australia in 1916 to service the health needs of a nation isolated by war. CSL Limited was then incorporated in 1991 and listed on the Australian Stock Exchange in 1994. CSL Limited is now a global specialty biotechnology company, headquartered in Parkville, Victoria, an inner suburb of Melbourne, that researches, develops, manufactures and markets products to treat and prevent serious human medical conditions. Today CSL has major facilities in Australia, Germany, Switzerland and the US, employs over 13,000 employees working in 27 countries.
In 2000 CSL doubled its size through the purchase of a Swiss plasma company, the Bern-based ZLB Bioplasma AG. In 2004, during a period of plasma oversupply, the company expanded again with the purchase of the German medical company Aventis Behring. The company was the 2nd Australian public company to have reached a share price of over $100 per share. CSL is a leading manufacturer in a US$7.5 billion plasma industry. CSL is also a major manufacturer in a US$2 billion influenza industry, with 40 years manufacturing experience and sales spanning 27 countries around the globe.
- Blood plasma derivatives
- Cell Culture Reagents
|Traded as||ASX: CSL|
|Founded||916 (Federal government department), 1994 (privatised)|
|Headquarters||Parkville, Melbourne, Victoria|
|Key people||Paul Perreault (CEO)|
|Products||blood plasma, vaccines, antivenom, other laboratory and medical products|
|Revenue||USD$5.000 billion (2013)|
|Net income||USD$1,216 million (2013)|
|Number of employees||13,000|